Subcutaneous mAb May Benefit High-Risk Outpatients With COVID-19
TUESDAY, April 12, 2022 (HealthDay News) — For high-risk outpatients with mild-to-moderate COVID-19, subcutaneously administered monoclonal antibody (mAb) treatment with casirivimab and imdevimab is associated with reduced risk for 28-day hospitaliza…
Learn MoreOverall Risk of Myopericarditis Low After COVID-19 Vaccine
TUESDAY, April 12, 2022 (HealthDay News) — Myopericarditis is rare following COVID-19 vaccination, with an overall incidence not differing significantly for those receiving COVID-19 vaccines or non-COVID-19 vaccines, according to a review published online April 11 in The Lancet Respiratory Medicine.
Ryan Ruiyang Ling, from the Yong Loo Lin School of Medicine in Singapore, and colleagues conducted a systematic review and meta-analysis to examine the incidence of myocarditis following vaccination. Data were included from 22 studies, with 405,272,721 vaccine doses.
The researchers found that the overall incidence of myopericarditis was 33.3 per million vaccine doses, with no significant difference seen for people who received COVID-19 vaccines and those who received non-COVID-19 vaccines (18.2 versus 56.0). The incidence of myopericarditis was significantly higher following smallpox vaccinations (132.1) compared with COVID-19 vaccination, but was not significantly different after influenza versus COVID-19 vaccination (1.3) or in studies reporting on other non-smallpox vaccinations (57.0). For those receiving COVID-19 vaccines, significantly higher incidence of myopericarditis was seen for males versus females, those aged
“The overall risk of myopericarditis appears to be no different for this newly approved group of vaccines against COVID-19, compared to vaccines against other diseases,” a coauthor said in a statement. “The risk of such rare events should be balanced against the risk of myopericarditis from infection and these findings should bolster public confidence in the safety of COVID-19 vaccinations.”
One author disclosed financial ties to Baxter.
Learn MoreDMARDs Not Linked to Alzheimer Risk for Seniors With RA
TUESDAY, April 12, 2022 (HealthDay News) — For patients with rheumatoid arthritis aged 65 years and older, the risk of Alzheimer disease and related dementia (ADRD) does not differ with tofacitinib, tocilizumab, or tumor necrosis factor (TNF) inhibit…
Learn MoreParental Cancer Tied to Poorer Health Outcomes in Children
TUESDAY, April 12, 2022 (HealthDay News) — Parental cancer is associated with school absenteeism, medical care unaffordability, increased health care use, and poor mental health among children, according to a study published online April 11 in JAMA Pediatrics.
Zhiyuan Zheng, Ph.D., from the American Cancer Society in Atlanta, and colleagues examined associations of parental cancer with children’s school absenteeism, medical care unaffordability, health care use, and mental health. Analysis included children (aged 5 to 17 years) living in families with (1,232 children) and without (33,870 children) a history of parental cancer and participating in the National Health Interview Survey (2010 to 2018).
The researchers found that a history of parental cancer was adversely associated with school absenteeism, medical care unaffordability, health care use, and mental health among children. When sequentially adjusting for child, parent, and family characteristics, the magnitude of the associations was reduced. In adjusted analysis, odds ratios for school absenteeism of one day or more declined from 1.33 (95 percent confidence interval, 1.11 to 1.59; P = 0.002) to 1.12 (95 percent confidence interval, 0.93 to 1.34; P = 0.23) and for any child hospital emergency department visit from 1.56 (95 percent confidence interval, 1.31 to 1.86; P
“Health care professionals and policies should consider the unique needs of affected children and develop school-, parent-, and family-directed strategies to ameliorate the negative associations between parental cancer and children’s health,” the authors write.
Several authors disclosed financial ties to AstraZeneca.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Learn MoreSGLT2 Inhibitors Reduce Heart Failure Hospitalization
TUESDAY, April 12, 2022 (HealthDay News) — For patients with heart failure, sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce hospitalization for heart failure and cardiovascular death, but increase the risk of genital infections, according to…
Learn MoreHealth Care Employee Turnover Recovering
MONDAY, April 11, 2022 (HealthDay News) — Turnover rates are returning to prepandemic levels across most groups of health care workers, according to a study published online April 8 in JAMA Health Forum.Bianca K. Frogner, Ph.D., from the University o…
Learn MoreCOVID-19-Associated Acute Myocarditis Reported in 2.4 Per 1,000 Patients
MONDAY, April 11, 2022 (HealthDay News) — Acute myocarditis (AM) occurs in 2.4 per 1,000 patients hospitalized for COVID-19, according to a study published in the April 12 issue of Circulation.Enrico Ammirati, M.D., Ph.D., from Niguarda Hospital in M…
Learn MoreProstate Cancer Biopsy, Diagnoses Down During the Pandemic
MONDAY, April 11, 2022 (HealthDay News) — Prostate biopsy and prostate cancer (PC) diagnosis rates decreased during the COVID-19 pandemic among U.S. veterans, according to a study published online April 7 in JAMA Oncology.Zachary Klaassen, M.D., from…
Learn MoreErectile Dysfunction Meds Tied to Higher Risk for Vision Issues
MONDAY, April 11, 2022 (HealthDay News) — Regular users of phosphodiesterase type 5 inhibitors (PDE5Is) for erectile dysfunction may have an increased risk for adverse ocular events, according to a study published online April 7 in JAMA Ophthalmology…
Learn MoreCOVID-19 Vaccine Largely Protects Cancer Patients
MONDAY, April 11, 2022 (HealthDay News) — Real-world evidence shows that patients with cancer have a higher risk for developing breakthrough COVID-19 infections and severe outcomes, according to a study published online March 14 in the Journal of Cli…
Learn More